Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis.

Brown, Timothy J; Mamtani, Ronac; Gimotty, Phyllis A; Karasic, Thomas B; Yang, Yu-Xiao

Brown, Timothy J; Mamtani, Ronac; Gimotty, Phyllis A; Karasic, Thomas B; Yang, Yu-Xiao.

Afiliación

Brown TJ; Abramson Cancer Center, University of Pennsylvania, 12 Perelman Ctr South Pavilion, 3400 Civic Center Blvd, Philadelphia, PA, 19104-4283, USA. Timothy.Brown3@pennmedicine.upenn.edu.
Mamtani R; Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia, PA, USA. Timothy.Brown3@pennmedicine.upenn.edu.
Gimotty PA; Abramson Cancer Center, University of Pennsylvania, 12 Perelman Ctr South Pavilion, 3400 Civic Center Blvd, Philadelphia, PA, 19104-4283, USA.
Karasic TB; Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia, PA, USA.
Yang YX; Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA.

J Cancer Res Clin Oncol ; 149(6): 2345-2354, 2023 Jun.

Article en En | MEDLINE | ID: mdl-36862158

Asunto(s)

Carcinoma Hepatocelular; Neoplasias Hepáticas; Enfermedad del Hígado Graso no Alcohólico; Humanos; Bevacizumab; Carcinoma Hepatocelular/tratamiento farmacológico; Neoplasias Hepáticas/tratamiento farmacológico; Etanol

Palabras clave

Hepatocellular carcinoma; Immunotherapy; NASH; Outcomes

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Enfermedad del Hígado Graso no Alcohólico / Neoplasias Hepáticas Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Cancer Res Clin Oncol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google